May 27, 2025
BioLineRx Reports First Quarter 2025 Financial Results and Provides Corporate Update
May 20, 2025
BioLineRx to Report First Quarter 2025 Results on May 27, 2025
Mar 24, 2025
BioLineRx to Report 2024 Annual Results on March 31, 2025
Jan 17, 2025
BioLineRx Announces Change to Ratio of American Depositary Shares to Ordinary Shares
Jan 06, 2025
BioLineRx Announces $10 Million Registered Direct Offering
Nov 25, 2024
BioLineRx Reports Third Quarter 2024 Financial Results and Provides Update on Transformation to Drive Shareholder Value
Nov 21, 2024
BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA® (motixafortide) through Gamida Cell Ltd.
Nov 20, 2024
BioLineRx to Report Third Quarter 2024 Results on November 25, 2024
Nov 05, 2024
BioLineRx Announces Oral Presentation on Data from Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease at ASH 2024
Sep 17, 2024
BioLineRx Launches 'Mobilization Matters': A Digital Resource for People with Multiple Myeloma Preparing for Stem Cell Collection
Aug 15, 2024
BioLineRx Reports Second Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates
May 30, 2024
BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applications in Sickle Cell Disease (SCD)
May 28, 2024
BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates
Apr 01, 2024
BioLineRx Announces $6 Million Registered Direct Offering
Mar 26, 2024
BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates
Mar 04, 2024
BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (BL-8040) Suitable for Large Scale Production
Feb 28, 2024
BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC)
Feb 16, 2024
BioLineRx Announces Acceptance of Two Poster Presentations on APHEXDA® (motixafortide) for CD34+ Hematopoietic Stem Cell (HSC) Mobilization in Patients with Multiple Myeloma at the 2024 Tandem Meetings of ASTCT® and CIBMTR®
Feb 23, 2021
BioLineRx Reports Year-End 2020 Financial Results and Provides Corporate Update
Feb 17, 2021
BioLineRx to Report Annual 2020 Results on February 23, 2021